A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Withdrawn before enrolling · Phase 3

Conditions studied: Non-Small Cell Lung Cancer

In brief

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

Key facts

Study ID

NCT03048136

Run by

Bristol-Myers Squibb

People needed

0

Starts

2018-03-09

Expected to finish

2019-09-29

Last updated by the study team

2018-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1) Stage IV or recurrent non-Small cell lung cancer
• 2) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
• 3) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization

You may not qualify if…

• 1) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
• 2) Active, known or suspected autoimmune disease or HIV infection
• 3) Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
• 4) Untreated Central Nervous System metastases
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution — San Francisco, California, United States
• Local Institution — Lincoln, Nebraska, United States
• Local Institution — Hackensack, New Jersey, United States
• Local Institution — Columbus, Ohio, United States
• Local Institution — Lancaster, Pennsylvania, United States
• Local Institution — Langhorne, Pennsylvania, United States
• Local Institution — Sayre, Pennsylvania, United States
• Local Institution — Charleston, South Carolina, United States
• Local Institution — St. George, Utah, United States
• Local Institution — Viedma, Río Negro Province, Argentina
• Local Institution — Montreal, Quebec, Canada
• Local Institution — Dresden, Germany
• Local Institution — Gauting, Germany
• Local Institution — Gerlingen, Germany
• Local Institution — Großhansdorf, Germany
• Local Institution — Lima, Peru
• Local Institution — Lima, Peru

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.